Black-Market Retatrutide: Two Death Reports to the FDA, Rising Poison Center Calls and Five More Lilly Lawsuits
The short version
- CBS News reported on 13 October that the FDA received two reports of deaths after people took products sold as retatrutide. Neither CBS nor the FDA has verified the reports, and a report alone does not show the drug caused a death.
- America's Poison Centers logged 862 retatrutide exposures in the three months to September, up from 460 in the previous three months and 249 in the first three months of 2026.
- Eli Lilly filed five more lawsuits against retatrutide sellers on 8 October, after six in August.
- Retatrutide is not approved anywhere. The FDA says it cannot be used in compounding, and Lilly plans to file for approval in the first quarter of 2027.
- In Australia, a vial labelled retatrutide that left a patient with a torn oesophagus contained no retatrutide at all, but about eight times the usual dose of semaglutide.
Retatrutide, Eli Lilly's experimental triple agonist, has become the most sought-after weight-loss compound on the grey market, years before it can be prescribed. In the past four weeks the record on what that market is selling, and what it is doing to people, has grown quickly. Here is what is documented as of 14 October 2026, and what is not.
Two deaths reported to the FDA
On 13 October CBS News reported that the FDA's Adverse Event Reporting System (FAERS) received two reports in recent months of deaths after people took products claiming to be retatrutide. CBS obtained the reports under the Freedom of Information Act.
- July: a healthcare professional reported that a 41-year-old woman with obesity went into cardiac arrest. The report lists retatrutide as a "suspect product" obtained "from an unreliable source". It also notes she was drinking kava at the time.
- September: a report that a 49-year-old patient died after severe dehydration, malnutrition and cardiac arrest. It says a licensed nurse "provided her the link and sold her vials and provided recommended dosages" from an online peptide vendor.
What these reports do not show: CBS says the details are not verified and "it is unclear whether the drug was to blame", and that the reports alone "don't prove that the drugs caused or contributed to patient deaths". The FDA declined to say whether it had verified either report. CBS notes that FAERS is designed to help the agency monitor the safety of drugs it has approved; each of these reports names retatrutide as a suspect product, which records a suspicion, not a finding. Eli Lilly said the reports "make clear the two individuals were taking black-market retatrutide".
Poison center calls more than tripled this year
CBS also reported figures from America's Poison Centers, which began tracking retatrutide exposures late last year:
| Quarter (2026) | Retatrutide exposures logged | Change |
|---|---|---|
| January to March | 249 | first quarter of 2026 |
| April to June | 460 | up 85% |
| July to September | 862 | up 87% |
Source: America's Poison Centers figures as reported by CBS News, 13 October 2026. The percentages are our arithmetic. A rise in calls for a newly tracked substance is partly a rise in awareness, as CBS notes, so the trend says more about how widely the product is used than about how dangerous each dose is.
The vial may not contain retatrutide at all
The clearest evidence about what is in grey-market vials comes from Australia. On 13 September ABC News reported a safety advisory from the Therapeutic Goods Administration (TGA): a patient suffered a torn oesophagus after using a product labelled retatrutide. The TGA said laboratory testing found the product contained no retatrutide, but undeclared semaglutide, and that "the amount of semaglutide detected was approximately eight times higher than the level found in semaglutide products assessed by the TGA". Lilly told CBS it has found suspect products "with too much, too little, or the wrong active ingredient". That is why our guide to peptide testing treats an identity test, not just a purity number, as the first thing to check on any certificate of analysis.
Lilly's lawsuits: five more on 8 October
Bloomberg Law reported that on Thursday 8 October Lilly filed five more lawsuits "across several federal courts", alleging the defendants unlawfully sell and promote copies of retatrutide. The defendants named are American Peptides LLC, LiveWell Peptides, Cenexa Labs LLC, Medrein Health & Aesthetics and Medshape Weight Loss Clinic LLC. These are allegations in civil complaints, not findings. They follow six suits Lilly filed in August against Aesthetic Envy, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide, which are in our enforcement tracker.
Where retatrutide actually stands
| Question | Answer on 14 October 2026 | Source |
|---|---|---|
| Is it approved? | No, not by the FDA or any other regulator we could find. | Lilly; FDA |
| When could it be? | Lilly: "Lilly plans to submit a Biologics License Application (BLA) in Q1 2027 to the U.S. Food and Drug Administration." | Lilly, 29 Sep 2026 |
| Can a pharmacy compound it? | No. FDA: "Retatrutide and cagrilintide cannot be used in compounding under federal law." | FDA GLP-1 page, current as of 1 Oct 2026 |
| What did the latest trial show? | TRIUMPH-2, adults with type 2 diabetes and obesity or overweight: "retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks" (efficacy estimand). Stopping for adverse events: 3.8% (4 mg), 11.6% (9 mg) and 7.7% (12 mg), against 4.9% on placebo. | Lilly, 29 Sep 2026 |
| Would the reported temporary peptide plan cover it? | Nothing reported says so, and the FDA position above rules out compounding it under current law. | Our fact check of the plan |
The full trial picture, including TRIUMPH-1 against tirzepatide's SURMOUNT-1, is in retatrutide vs tirzepatide, and the side effects reported in the trials are in retatrutide side effects.
Questions readers ask
Has anyone died from retatrutide?
Two deaths after people took products sold as retatrutide were reported to the FDA in 2026, according to CBS News on 13 October. The reports are unverified, the FDA would not say whether it checked them, and they do not establish that the product caused the deaths. Lilly says both people were using black-market retatrutide.
Is retatrutide FDA approved?
No. Eli Lilly plans to submit a Biologics License Application to the FDA in the first quarter of 2027. Anything sold as retatrutide today is unapproved.
Can a compounding pharmacy make retatrutide?
No. The FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law (page current as of 1 October 2026).
Does grey-market retatrutide actually contain retatrutide?
Not always. In an Australian case reported on 13 September 2026, the regulator found a vial labelled retatrutide contained no retatrutide but about eight times the usual dose of semaglutide. Lilly says it has found products with too much, too little or the wrong ingredient.
Who is Eli Lilly suing over retatrutide?
Six sellers in August 2026 and five more on 8 October 2026: American Peptides LLC, LiveWell Peptides, Cenexa Labs LLC, Medrein Health and Aesthetics and Medshape Weight Loss Clinic LLC. The claims are allegations, not findings.
Sources
- CBS News: Two deaths were reported to the FDA. Is the bootleg weight-loss drug "Reta" to blame? (Daniel Gilbert), 13 October 2026
- Bloomberg Law: Eli Lilly sues more vendors selling 'illicit' weight loss drugs (Nyah Phengsitthy), 8 October 2026
- ABC News (Australia): Patient suffers torn oesophagus after using unapproved peptide (Rachel Carbonell), 13 September 2026
- Eli Lilly: TRIUMPH-2 results and BLA timing (PR Newswire), 29 September 2026
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss, content current as of 1 October 2026
- Eli Lilly: August 2026 lawsuits and referrals (news release), 12 August 2026